Вы находитесь на странице: 1из 3

DAFTAR PUSTAKA

1. Neil J. Friedman, M.D., Peter K. Kaiser, M.D. Essentials of Ophthalmology. Philadelphia :


Elsevier Health Sciences, 2007, pp 233.
2. Rajesh.P MD, Dheeresh .K

MS, Safarulla M.A MS,

Shaji Hussain

MS. Vitreous

Hemorrhage. Kerala Journal of Ophthalmology. Vol. XXIII, No.3, Sept. 2011.


3. Ralph C. Eagle. Eye Pathology : An Atlas and Text. Philadelphia : Lippincott Williams and
Wilkins, a Wolters Kluwer Business, 2011, pp 137-139.
4. Ferenc Kuhn, Dante Pieramici. Ocular Trauma: Principles and Practice. New York : Thieme
Medical Pubilshers, 2002, pp 61-64.
5. Kuldev Singh,William E. Smiddy,Andrew G. Lee: Ophthalmology Review: A Case Study
Approach. New York: Thieme Medical Publishers, Inc, 2001, pp 172-174

6.

Ahmadieh H, Moradian S, Malihi M.Rapid regression of extensive

retinovitreal

neovascularization secondary to branch retinal vein occlusion after a single intravitreal


injection of bevacizumab. Int Ophthalmol. 2005; 26:191-3.

7. Abhish

R.Bhavsar,Lisa R Grillone,Timothy R Mc Namara, James A.

M.Hochberg,Ronald K Pearson. Predicting response of

Gow, Alan

vitreous hemorrhage after

intravitreous injection of highly purified ovine Hyaluronidase (vitrase) in patients with


diabetes. Invest Ophthalmol Vis Sci.2008; 49:4219-25.

8. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR; Vitrase

for Vitreous Hemorrhage

Study Groups. Pooled efficacy results from two multinational randomized controlled clinical
trials of a single intravitreous injection of highly purified ovine Hyaluronidase (Vitrase) for
the management of vitreous hemorrhage. Am J Ophthalmol. 2005; 140:573-84.

9. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR; Vitrase

for Vitreous Hemorrhage

Study Groups. Safety results of two phase III trials of an intravitreous injection of highly
purified ovine Hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J
Ophthalmol. 2005; 140:585-97.

10.

Schachat AP, Oyakawa RT, Michels RG, Rice TA.Complications of vitreous surgery for

diabetic retinopathy. II. Postoperative complications. Ophthalmology. 1983; 905:522-30.

11.

Wayne R. Lo, Stephen J. Kim, Thomas M. Aaberg, Sr., Christopher Bergstrom, Sunil

Srivastava, Jiong Yan, Daniel F. Martin, G. Baker Hubbard.Visual Outcomes and Incidence
of Recurrent Vitreous Hemorrhage after Vitrectomy in Diabetic Eyes Pretreated with
Bevacizumab (Avastin) . Retina. 2009; 29: 926931.

12.

Yang CM, Yeh PT, Yang CH.Intravitreal long-acting gas in the prevention of early

postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology. 2007; 114:710-5.

13.

Ahn J, Woo SJ, Chung H, Park KH.The Effect of Adjunctive Intravitreal Bevacizumab

for Preventing Postvitrectomy Hemorrhage

in Proliferative Diabetic Retinopathy.

Ophthalmology. 2011.
14. Rajesh.P MD, Dheeresh .K MS, Safarulla M.A MS, Shaji Hussain MS. Vitreous Hemorrhage.
Kerala Journal of Ophthalmology. Sep 2011; XXII (3):192-195.
15. Medscape. Vitreous Hemorrhage Treatment & Management. Author: Brian A Phillpotts, MD;
Chief Editor: Hampton Roy Sr, MD. http://emedicine.medscape.com/article/1230216treatment. 2010.
16. Bothun ED, Groth SL, Freedman SF. Vitreous hemorrhage after trabeculotomy in aphakic
eyes. J AAPOS. Apr 18 2013;

17. Sato T, Morita S, Bando H, Sato S, Ikeda T, Emi K. Early vitreous hemorrhage after
vitrectomy with preoperative intravitreal bevacizumab for proliferative diabetic retinopathy.
Middle East Afr J Ophthalmol. Jan 2013;20(1):51-5.
18. Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative
vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane
Database Syst Rev. May 11 2011;5:CD008214.